Low-dose melphalan in elderly acute myeloid leukaemia: complete remissions but resistant relapse with therapy-related karyotypes TO 
THE EDITOR
Treatment of acute myeloid leukaemia (AML) in the elderly remains a difficult challenge and the prognosis is generally poor. This is in part due to a high frequency of adverse prognostic parameters such as karyotype and expression of multidrug resistance proteins. It is also due to the reduced ability to tolerate intensive chemotherapy. Chemotherapeutic approaches which can induce a remission with minimal toxicity are therefore of considerable potential use in these patients. We present two cases of elderly patients with AML who initially had complete remissions following treatment with low-dose melphalan but subsequently relapsed with resistant disease. At resistant relapse both had similar karyotypes with characteristic therapy-related abnormalities.
A 74-year-old female presented with red cell macrocytosis and pancytopenia in April 1997. Bone marrow biopsy showed 25% myeloblasts, trilineage dysplasia, mild hypocellularity and normal karyotype. She was initially treated with red cell transfusions 6 weekly and remained well with relatively few problems secondary to infection or bleeding. However, by January 1998 her transfusion requirements had increased to 3 weekly and we therefore commenced a trial of oral melphalan 2 mg/day. Following 2 months of treatment our patient was clinically in complete remission with a normal full blood count. This was sustained until November 1998 when a further 2-month course was administered resulting in a second remission until May 1999. A third course of melphalan at this time proved to be ineffective. At resistant second relapse her bone marrow biopsy showed 95% myeloblasts. Cytogenetic analysis and fluorescent in situ hybridisation (FISH) using whole chromosome paints for chromosomes 17 and 20 was carried out. These revealed a derivative chromosome 17 as a result of a translocation between chromosomes 17 and 20. The breakpoint on the short arm (p) of chromosome 17 was further characterised using FISH probes for the p53 and Smith Magenis (SMS) loci. p53 and SMS loci were lost confirming the breakpoint to be centromeric to SMS (17p11.2). No response was seen to subcutaneous cytarabine 20 mg twice a day for 10 days and the patient died following an intracerebral bleed in October 1999.
A 79-year-old male presented in September 1996 with red cell macrocytosis, neutropenia and thrombocytopenia. Bone marrow biopsy showed evidence of dysplasia with 8% myeloblasts and a normal karyotype. He remained well with no infective or bleeding problems and did not require red cell transfusions until June 1997. Increasing transfusion requirements led to repeat bone marrow biopsy in January 1998 and this showed 70% myeloblasts with a markedly hypocellular trephine. Cytogenetic analysis remained normal. He was treated with low-dose melphalan 2 mg/day for 2 months resulting in clinical complete remission. Falling neutrophil and platelet counts led to a repeat course of melphalan in September 1998, resulting in remission until April 1999. At this time both intravenous cytarabine 180 mg/day for 5 days and subsequently a further course of oral melpalan were inef- fective. Repeat bone marrow biopsy showed 38% myeloblasts. Cytogenetic analysis and FISH now revealed a derivative chromosome 17 as a result of a translocation between chromosomes 17 and 20. FISH confirmed loss of p53 but retention of SMS. The patient died from gram-negative sepsis in September 1999. Low-dose melphalan has therapeutic activity in selected patients with high risk myelodysplastic syndrome (MDS) 1 and secondary acute myeloid leukaemia. 2 The mean total dose of melphalan required is 140 mg (70 days treatment). It is well tolerated with few infections and low transfusion requirements. Cost of treatment is also very low. Overall the complete remission (CR) rate is around 30%, but if patients with normal karyotypes or hypocellular marrows are selected the CR achieved rises to 60-75%. If CR is achieved, median survival is 27 months compared with 6.5 months in those not achieving CR. 1 Deletions of 17p are a well recognized therapy-related karyotype in MDS and AML, commonly resulting from monosomy 17, i(17q) and unbalanced translocations between chromosome 17 and other chromosomes. Partner chromosomes involved in these translocations include 5, 7, 12, 18, 21 and 22, whilst chromosome 20 is only rarely reported. 3 In a recent study of 25 cases of MDS/AML with therapyrelated 17p deletion, four patients had received prior melphalan. 4 The emergence of a t(17:20) clone in our patients coincided with clinical resistance to melphalan. Thus, whilst low-dose melphalan is a useful therapeutic option in selected elderly patients with AML, its use as a single agent may be inappropriate in younger patients. 
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